2007•Unpublished venueRequires access

Bioequivalence Evaluation of Two Telmisartan Tablets in Healthy Volunteers

Dong-Xiang Zeng, Ren Huayi, Kunyan Li, Lizhi Cao, Song Jian-ping

Open publisher page 0 citations

Abstract

目的:研究国产(受试制剂)与进口(参比制剂)替米沙坦片的人体生物等效性.方法:采用LC-MS法,测定18名健康男性单次交叉口服参比制剂及受试制剂80 mg后血浆中不同时间点的药物浓度,计算其药动学参数和相对生物利用度.结果:受试制剂及参比制剂的主要药物动力学参数Cmax分别为(428.8±108.6)和(420.7±93.0)ng·h-1·ml-1;tmax分别为(1.0±0.3)和(1.3±0.5)h;AUC0-96分别为(3 041.8±409.4)和(3 144.1±260.4)ng·h-1·ml-1.受试制剂相对生物利用度为96.8%±10.6%.结论:受试制剂与参比制剂具有生物等效性.

About this research paper

What this paper is about

目的:研究国产(受试制剂)与进口(参比制剂)替米沙坦片的人体生物等效性.方法:采用LC-MS法,测定18名健康男性单次交叉口服参比制剂及受试制剂80 mg后血浆中不同时间点的药物浓度,计算其药动学参数和相对生物利用度.结果:受试制剂及参比制剂的主要药物动力学参数Cmax分别为(428.8±108.6)和(420.7±93.0)ng·h-1·ml-1;tmax分别为(1.0±0.3)和(1.3±0.5)h;AUC0-96分别为(3 041.8±409.4)和(3 144.1±260.4)ng·h-1·ml-1.受试制剂相对生物利用度为96.8%±10.6%.结论:受试制剂与参比制剂具有生物等效性.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

目的:研究国产(受试制剂)与进口(参比制剂)替米沙坦片的人体生物等效性.方法:采用LC-MS法,测定18名健康男性单次交叉口服参比制剂及受试制剂80 mg后血浆中不同时间点的药物浓度,计算其药动学参数和相对生物利用度.结果:受试制剂及参比制剂的主要药物动力学参数Cmax分别为(428.8±108.6)和(420.7±93.0)ng·h-1·ml-1;tmax分别为(1.0±0.3)和(1.3±0.5)h;AUC0-96分别为(3 041.8±409.4)和(3 144.1±260.4)ng·h-1·ml-1.受试制剂相对生物利用度为96.8%±10.6%.结论:受试制剂与参比制剂具有生物等效性.

Key concepts: Bioequivalence, Telmisartan, Medicine, Pharmacology, Pharmacokinetics, Internal medicine, Blood pressure

Related papers

Back to paper searchBrowse research topicsOriginal source
Bioequivalence Evaluation of Two Telmisartan Tablets in Healthy Volunteers — Research Paper | ScholarLens